{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:47:27Z","timestamp":1785808047539,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109173","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:22:04Z","timestamp":1761668524000},"page":"109173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Novel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer"],"prefix":"10.1016","volume":"166","author":[{"given":"Mostafa G.M.","family":"El-Gazzar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally S.","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Ghorab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa G.","family":"El-Gazzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109173_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120334","article-title":"Novel imidazo [1, 2-a] pyridine derivatives induce apoptosis and cell cycle arrest in non-small cell lung cancer by activating NADPH oxidase mediated oxidative stress","volume":"294","author":"Bhavya","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109173_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bioorg.2025.109173_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/resp.13870","article-title":"Radiotherapy treatment for lung cancer: current status and future directions","volume":"25","author":"Vinod","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.bioorg.2025.109173_bb0020","series-title":"StatPearls [Internet]","article-title":"Physiology, tyrosine kinase receptors","author":"Wintheiser","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109173_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105164","article-title":"Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: their relevance for cancer therapy","volume":"161","author":"Liang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.109173_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0035","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109173_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105393","article-title":"Epidermal growth factor receptor inhibitors as potential anticancer agents: an update of recent progress","volume":"116","author":"Sharma","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0045","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non\u2013small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.109173_bb0050","doi-asserted-by":"crossref","first-page":"00676","DOI":"10.1183\/23120541.00676-2023","article-title":"Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib","volume":"10","author":"Liang","year":"2024","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.bioorg.2025.109173_bb0055","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1038\/s41467-018-07078-0","article-title":"Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors","volume":"9","author":"Fassunke","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109173_bb0060","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0281","article-title":"AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients","volume":"15","author":"Xu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109173_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109173_bb0070","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-22-2072","article-title":"FDA approval summary: Mobocertinib for metastatic non\u2013small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109173_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2015.12.017","article-title":"Pyrrole: an emerging scaffold for construction of valuable therapeutic agents","volume":"110","author":"Gholap","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejmech.2018.08.023","article-title":"Pyrrolopyrimidines: an update on recent advancements in their medicinal attributes","volume":"157","author":"Pathania","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2018.08.002","article-title":"Pyrrole: an insight into recent pharmacological advances with structure activity relationship","volume":"157","author":"Ahmad","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/1061186X.2019.1703189","article-title":"Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety","volume":"28","author":"Kuznietsova","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bioorg.2025.109173_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112783","article-title":"Bioactive pyrrole-based compounds with target selectivity","volume":"208","author":"Petri","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0100","unstructured":"P.K. SR, Design Synthesis and Development of Pyrrole Scaffolds as Antitubercular Agents, in, Rajiv Gandhi University of Health Sciences (India), (2022) 30283449."},{"key":"10.1016\/j.bioorg.2025.109173_bb0105","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s11030-022-10387-8","article-title":"Therapeutic potential of pyrrole and pyrrolidine analogs: an update","volume":"26","author":"Jeelan Basha","year":"2022","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2025.109173_bb0110","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2174\/0113852728306820240515054401","article-title":"Developments of pyrrolo [2, 3-d] pyrimidines with pharmaceutical potential","volume":"28","author":"Rashad","year":"2024","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0115","article-title":"Pyrrolo [2, 3-d] pyrimidines as potential kinase inhibitors in cancer drug discovery: a critical review","volume":"153","author":"Madhurya","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113711","article-title":"The synthesis and bioactivity of pyrrolo [2, 3-d] pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations","volume":"224","author":"Xia","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bioorg.2018.10.060","article-title":"Design, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives","volume":"83","author":"Kilic-Kurt","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104669","article-title":"Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors","volume":"108","author":"Sayed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2017.09.061","article-title":"Discovery of benzo [g] quinazolin benzenesulfonamide derivatives as dual EGFR\/HER2 inhibitors","volume":"141","author":"Alsaid","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0140","article-title":"New alkanesulfonate-based quinazolinone-acetohydrazide scaffolds: rational design, synthesis, molecular docking, anticancer properties and potential EGFR and its T790M\/L858R mutants inhibitors","volume":"108405","author":"Morsy","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0145","doi-asserted-by":"crossref","unstructured":"A. Belal, N.M. Abdel Gawad, A.B. Mehany, M.A. Abourehab, H. Elkady, A.A. Al-Karmalawy, A.S. Ismael, Design, synthesis and molecular docking of new fused 1 H-pyrroles, pyrrolo [3, 2-d] pyrimidines and pyrrolo [3, 2-e][1, 4] diazepine derivatives as potent EGFR\/CDK2 inhibitors, J. Enzyme Inhib. Med. Chem., 37 (2022) 1884-1902, Doi: https:\/\/doi.org\/10.1080\/14756366.2022.2096019.","DOI":"10.1080\/14756366.2022.2096019"},{"key":"10.1016\/j.bioorg.2025.109173_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112889","article-title":"Discovery of fast-acting dual-stage antimalarial agents by profiling pyridylvinylquinoline chemical space via copper catalyzed azide-alkyne cycloadditions","volume":"209","author":"Huang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2025.109173_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2025.109173_bb0165","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.109173_bb0170","first-page":"15","article-title":"Lung cancer epidermal growth factor receptor mutations and radiotherapy response: a multicentre clinical study","volume":"30","author":"Hsu","year":"2021","journal-title":"ctRO"},{"key":"10.1016\/j.bioorg.2025.109173_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.radonc.2018.05.014","article-title":"Radiotherapy utilization in developing countries: an IAEA study","volume":"128","author":"Rosenblatt","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bioorg.2025.109173_bb0180","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2015.04.018","article-title":"The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis","volume":"116","author":"Borr\u00e0s Andr\u00e9s","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bioorg.2025.109173_bb0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1126\/science.aaf7532","article-title":"The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury","volume":"354","author":"Hu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109173_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005148","article-title":"New paradigms and future challenges in radiation oncology: an update of biological targets and technology","volume":"5","author":"Liauw","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109173_bb0195","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.saep.2005.07.001","article-title":"Principles and practice of radiation therapy in exotic and avian species","author":"Mauldin","year":"2005","journal-title":"Semin. Avian. Exotic. Pet. Med."},{"key":"10.1016\/j.bioorg.2025.109173_bb0200","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/jcmm.17760","article-title":"Inactivation of EGFR\/ERK\/NF-? B signalling associates with radiosensitizing effect of 18\u00df-glycyrrhetinic acid on progression of hepatocellular carcinoma","volume":"27","author":"Yu-Chang","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109173_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108470","article-title":"Novel chloropyridazine sulfonamides as aromatase inhibitors and apoptotic inducers in breast cancer","volume":"160","author":"Zahran","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0210","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109173_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cells13221838","article-title":"Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications","volume":"13","author":"Mustafa","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109173_bb0220","doi-asserted-by":"crossref","first-page":"12361","DOI":"10.1021\/acsomega.1c01604","article-title":"Design, synthesis, anticancer evaluation, enzymatic assays, and a molecular modeling study of novel pyrazole\u2013indole hybrids","volume":"6","author":"Hassan","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.109173_bb0225","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2013.855307","article-title":"Targeting the apoptosis pathway in hematologic malignancies","volume":"55","author":"Zaman","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bioorg.2025.109173_bb0230","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/ijms19020448","article-title":"Apoptosis: a target for anticancer therapy","volume":"19","author":"Pfeffer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109173_bb0235","doi-asserted-by":"crossref","unstructured":"G. Huang, H.-R. Zhao, Q.-Q. Meng, Q.-J. Zhang, J.-Y. Dong, B.-q. Zhu, S.-S. Li, Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents, Eur. J. Med. Chem., 143 (2018) 166\u2013181, Doi: https:\/\/doi.org\/10.1016\/j.ejmech.2017.11.031.","DOI":"10.1016\/j.ejmech.2017.11.031"},{"key":"10.1016\/j.bioorg.2025.109173_bb0240","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202402281","article-title":"Quinoline based thiazolidinediones: design, synthesis, in silico, in vitro, antioxidant and antidiabetic evaluation","volume":"9","author":"Mohd","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109173_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109173_bb0255","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/ci500467k","article-title":"iLOGP: a simple, robust, and efficient description of n-octanol\/water partition coefficient for drug design using the GB\/SA approach","volume":"54","author":"Daina","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.109173_bb0260","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.109173_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138741","article-title":"Pyridine-based glycosides bearing 1, 2, 4-triazole and their 1, 3, 4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: design, synthesis, antiproliferative activity and in silico studies","volume":"1313","author":"Kassem","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109173_bb0270","first-page":"2567","article-title":"New pyrano-pyridine conjugates as potential anticancer agents: design, synthesis and computational studies, future","volume":"16","author":"Srour","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109173_bb0275","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3748\/wjg.v11.i19.2990","article-title":"Docetaxel shows radiosensitization in human hepatocellular carcinoma cells","volume":"11","author":"Geng","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2025.109173_bb0280","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/14756366.2017.1279155","article-title":"Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline\/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents","volume":"32","author":"Eldehna","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:45:22Z","timestamp":1766101522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"alternative-id":["S0045206825010533"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109173","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109173"}}